Astellas president jumps to a new Frontier; Grifols chairman named CEO, breaking family tradition
→ Andrew Krivoshik has jumped ship at Astellas to become CMO at Frontier Medicines, a substantial get for Chris Varma and his precision medicines crew focused on undruggables. Krivoshik joined Astellas from Abbott in 2011 and was the oncology therapeutic area head at the Japanese pharma when the Seagen-partnered antibody-drug conjugate Padcev notched a full FDA approval in 2021.
Since then, Krivoshik ascended to SVP and head of development therapeutic areas, and then president and head of development in April 2022. AbbVie paid $55 million upfront in a December 2020 protein degradation pact with Frontier, which wants to challenge Amgen and Mirati in the KRAS space.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters